India: IPO Rejects Compulsory Licensing Application Against The Patented Drug SAXAGLIPTIN By Lee Pharma

Last Updated: 25 February 2016
Article by Saipriya Balasubramanian

Most Read Contributor in India, September 2016


An application for Compulsory Licensing against 'SAXAGLIPTIN' drug was filed by Lee Pharma, a Hyderabad based Indian pharma company, dated 29.06.2015.'SAXAGLIPTIN' is protected by the patent IN 206543 entitled "A Cyclopropyl-fused pyrrolidinebased compound" granted to Bristol Myers Squibb (BMS) which was subsequently assigned to AstraZeneca by way of deed of assignment. An order issued by IPO on 12th August, 2015, rejecting the application under Rule 97(1) of the Patent Rules, 2003. The Applicant requested a further hearing which was granted on 15/12/2015 along with supplementary submissions on 29/12/2015. Subsequent to this hearing, the IPO passed an order1 dated 19/01/2016 in which the Controller rejected the application for largely the same reasons as stated in its earlier order.

Facts of the case:

SAXAGLIPTIN is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor used in the treatment of Type II Diabetes Mellitus. The drug SAXAGLIPTIN is sold under the brand name 'ONGLYZA' in dosages of 2.5 mg and 5 mg. SAXAGLIPTIN in combination with Metformin is sold under the brand name 'KOMBIGLYZE XR' in dosage 5/500 mg and 5/1000 mg.

Grounds relied by the Applicant for making an application for Compulsory Licensing:

Section 84(1) (a): That the reasonable requirements of the public with respect to the patented invention have not been satisfied

The Applicant submitted that there are nearly 60 million people in India suffering from Type II DM and even if 1 million people were prescribed SAXAGLIPTIN then total number of tablets required for one million patients in one year would be 365,000,000 tablets per year. From Form-27 data submitted by the patentee , the Applicant mentioned the total number of ONGLYZA and KOMBIGLYZE imported for the whole year was

0.23% of the total number required for a year. Hence the Applicant submitted that there is more than 99% of shortage of SAXAGLIPTIN in the Indian market. Upon hearing the arguments of the Applicant, the Learned Controller insisted on authentic report for the data provided on increased diabetic population as well as the number of Type-II DM patients taking prescribed medicines in relation to other steps such as lifestyle change, dietary changes, exercise etc, but the Applicant could not provide authentic data.

Further, the Applicant did not provide any comparative data of SAXAGLIPTIN and other DPP-4 inhibitors such as Linagliptin, Sitagliptin and Vildagliptin which are also available in Indian market so that the reasonable requirements of the public in respect to SAXAGLIPTIN could be arrived. The learned Controller quoted the matter of 'Bayer Corporation Vs Union of India & Ors' which held that in respect of medicines the adequate test has to be 100% i.e to the fullest extent.

Hence the Controller stated that it was unclear from the Applicant's submission whether one million patients need SAXAGLIPTIN despite other alternatives such as Linagliptin, Sitagliptin and Vildagliptin. In the absence of authentic data, there is no way to understand the exact requirements of SAXAGLIPTIN in Indian market to decide or not whether the patentee is meeting with the reasonable requirements of the public in respect to patented invention.

With regards to the above mentioned details, the Controller stated that a prima facie case has not been made out by the Applicant to the effect that the reasonable requirements of the public with respect to the patented invention are not being satisfied and therefore, no case is made out in terms of Clause (a) of section 84 of the Indian Patents Act.

Section 84(1)(b) – That the patented invention is not available to the public at a reasonably affordable price

The Applicant submitted that excessive high price of SAXAGLIPTIN is a barrier for the poor patients in India hence, it is unavailable to a general public at a reasonably affordable price. The Controller again quoted Bayer v. Union of India to hold that the Controller does not have any power of investigations to arrive at a reasonably affordable price, and that such a price must be arrived at on the basis of evidence led by the parties.

The Controller observed that the prices of other DPP-4 inhibitors available in the Indian market despite such large volumes and side effects are also in the same range (Rs.42 to 58) which are at par with the patentee's SAXAGLIPTIN (i.e Rs.41 to 49) based on the daily requirements. Based on the figures submitted by the patentee in Form-27 on 10/02/2014 the Applicant calculated the cost of importing one tablet of ONGLYZA and KOMBIGLYZE in India by the Patentee is only about Rs.0.80 and Rs.0.92 respectively. But the Applicant priced two medicines ONGLYZA and KOMBIGLYZE in the range of Rs.41 to 49 per tablet. Therefore, the Applicant alleged that the patentee remain a monopoly due to high pricing of the drugs despite the small amount of cost involved in manufacturing/importing a single tablet.

However, ironically the Applicant in its application for Compulsory Licensing initially proposed it selling price as Rs.27 to 32 per tablet but eventually revised its price during hearing held on 15/12/2015 in the range of Rs.11 to 16.

It was highlighted by the Controller that the Applicant in its submissions has not furnished the details of reasonable requirements of the public with respect to SAXAGLIPTIN, the comparative requirements of SAXAGLIPTIN and other DPP-4 inhibitors Lindagliptin, Sitagliptin and Vildagliptin or any authentic data or statistics on SAXAGLIPTIN prescription by the doctors over the other DPP-4 inhibitors. Hence in the absence of all the critical data above, the question of SAXAGLIPTIN'S availability and affordability can't be determined. Therefore the Applicant failed to prima facie show that the patented invention is not available to the public at a reasonably affordable price.

Section 84 (1) (c): That the patented invention is not worked in the territory of India

The Controller in this regard reasoned his findings from the judgment of Honorable Bombay High Court in the Bayer case, that to manufacture in India is not a necessary pre condition in all cases to establish patent's working in India. However, the onus is on the patent holder to establish the reasons which make it impossible to manufacture the patented drug in India, particularly when the Patentee has manufacturing facilities within the country. Hence the Controller stated that in the present application since the Applicant has failed to show the exact requirement of SAXAGLIPTIN in terms of the number of patients requiring it or whether it is in shortage, it is very difficult to conclude whether manufacturing in India is necessary or not.


In the above case, the Applicant has failed to provide evidence along with application or during hearing or supplementary submission. Further, the Applicant had failed to convince the Controller regarding any of the grounds specified under Section 84(1) of the Patents Act, therefore the Controller rejected the application for Compulsory License with a view that a prima facie case has not been made out under Section 84 of the Indian Patents Act.


1 Application_20January2016.pdf

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.